Nuvectis Pharma (NVCT) Competitors $7.77 +0.04 (+0.53%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NVCT vs. DAWN, ATAI, AUTL, XNCR, ABVX, TLRY, MRVI, PRME, RLAY, and ABUSShould you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Day One Biopharmaceuticals (DAWN), atai Life Sciences (ATAI), Autolus Therapeutics (AUTL), Xencor (XNCR), Abivax (ABVX), Tilray Brands (TLRY), Maravai LifeSciences (MRVI), Prime Medicine (PRME), Relay Therapeutics (RLAY), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry. Nuvectis Pharma vs. Its Competitors Day One Biopharmaceuticals atai Life Sciences Autolus Therapeutics Xencor Abivax Tilray Brands Maravai LifeSciences Prime Medicine Relay Therapeutics Arbutus Biopharma Day One Biopharmaceuticals (NASDAQ:DAWN) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk. Which has higher valuation & earnings, DAWN or NVCT? Nuvectis Pharma has lower revenue, but higher earnings than Day One Biopharmaceuticals. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDay One Biopharmaceuticals$131.16M5.59-$95.50M-$0.71-10.19Nuvectis PharmaN/AN/A-$19M-$1.13-6.88 Do insiders and institutionals have more ownership in DAWN or NVCT? 88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 6.2% of Day One Biopharmaceuticals shares are owned by company insiders. Comparatively, 30.5% of Nuvectis Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is DAWN or NVCT more profitable? Nuvectis Pharma has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -42.66%. Day One Biopharmaceuticals' return on equity of -14.98% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Day One Biopharmaceuticals-42.66% -14.98% -13.04% Nuvectis Pharma N/A -148.83%-95.60% Which has more risk & volatility, DAWN or NVCT? Day One Biopharmaceuticals has a beta of -1.27, suggesting that its share price is 227% less volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of -0.25, suggesting that its share price is 125% less volatile than the S&P 500. Does the media favor DAWN or NVCT? In the previous week, Day One Biopharmaceuticals had 2 more articles in the media than Nuvectis Pharma. MarketBeat recorded 4 mentions for Day One Biopharmaceuticals and 2 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.93 beat Day One Biopharmaceuticals' score of 0.89 indicating that Nuvectis Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Day One Biopharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvectis Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend DAWN or NVCT? Day One Biopharmaceuticals presently has a consensus target price of $29.00, indicating a potential upside of 300.83%. Nuvectis Pharma has a consensus target price of $17.00, indicating a potential upside of 118.76%. Given Day One Biopharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Day One Biopharmaceuticals is more favorable than Nuvectis Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryDay One Biopharmaceuticals beats Nuvectis Pharma on 9 of the 16 factors compared between the two stocks. Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVCT vs. The Competition Export to ExcelMetricNuvectis PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$162.11M$3.04B$5.72B$9.52BDividend YieldN/A2.40%4.60%3.99%P/E Ratio-6.8721.1228.0720.02Price / SalesN/A340.60462.58104.32Price / CashN/A43.2336.5558.97Price / Book15.548.338.645.90Net Income-$19M-$55.19M$3.24B$258.50M7 Day Performance-0.37%5.91%4.08%2.12%1 Month Performance0.40%17.69%10.68%12.62%1 Year Performance17.39%5.36%34.47%19.25% Nuvectis Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVCTNuvectis Pharma2.7237 of 5 stars$7.77+0.5%$17.00+118.8%+11.2%$162.11MN/A-6.878DAWNDay One Biopharmaceuticals2.7169 of 5 stars$6.40flat$29.00+353.1%-53.2%$648.72M$131.16M-9.0160News CoverageATAIatai Life Sciences3.437 of 5 stars$3.53+9.3%$9.00+155.0%+147.7%$647.09M$310K-3.8880Gap UpHigh Trading VolumeAUTLAutolus Therapeutics2.6099 of 5 stars$2.43+0.8%$9.32+283.5%-38.5%$641.40M$10.12M-2.76330Gap UpXNCRXencor4.5069 of 5 stars$9.10+1.4%$28.00+207.7%-54.7%$638.40M$110.49M-2.97280ABVXAbivax2.4006 of 5 stars$10.14+1.9%$31.00+205.7%+488.7%$631.55MN/A0.0061Trending NewsAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeTLRYTilray Brands1.8236 of 5 stars$0.67+8.4%$1.92+184.6%-60.7%$625.34M$210.48M-0.642,650Upcoming EarningsOptions VolumeMRVIMaravai LifeSciences3.6062 of 5 stars$2.38-2.1%$6.64+178.9%-67.3%$618.82M$259.18M-2.09610Options VolumePRMEPrime Medicine3.853 of 5 stars$4.57+10.7%$9.25+102.4%-20.8%$614.65M$3.85M-2.23234Gap DownHigh Trading VolumeRLAYRelay Therapeutics2.6502 of 5 stars$3.63+3.7%$17.67+386.7%-58.8%$600.06M$10.01M-1.63330News CoverageABUSArbutus Biopharma2.2729 of 5 stars$3.14+0.3%$5.50+75.2%-16.3%$599.48M$6.17M-7.6690 Related Companies and Tools Related Companies DAWN Alternatives ATAI Alternatives AUTL Alternatives XNCR Alternatives ABVX Alternatives TLRY Alternatives MRVI Alternatives PRME Alternatives RLAY Alternatives ABUS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVCT) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
